|
CA2890860A1
|
|
Plant compositions and methods and uses thereof for treating elevated glucocorticoid related disorders, and anxiety
|
|
WO2014071506A1
|
|
Compounds for reducing glucocorticoids, and methods of treatment thereof
|
|
AU2011232816A1
|
|
Use of imatinib to treat liver disorders and viral infections
|
|
AU2010317683A1
|
|
Non-DNA base-containing polynucleotide compositions and their use for the modulation of immune responses
|
|
WO2007101337A1
|
|
Methods and compositions comprising bacterial type hi secreted proteins for mucosal immunization of animals
|
|
AU2007200536A1
|
|
Therapeutically useful synthetic oligonucleotides
|
|
WO2006026853A1
|
|
Prickly ash preparations and uses thereof as antiviral agents
|
|
AP200603863A0
|
|
Use of imatinib to treat liver disorders and viralinfections
|
|
WO2004103388A2
|
|
Insect repellent
|
|
US7371734B2
|
|
Oligonucleotide compositions and their use for the modulation of immune responses
|
|
US7662792B2
|
|
Modulation of Fas and FasL expression
|
|
AU2002341264B2
|
|
Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
|
|
MXPA04001315A
|
|
Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides.
|
|
CA2445202A1
|
|
Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
|
|
US7087586B2
|
|
Oligonucleotide compositions and their use to induce differentiation of cells
|
|
AU6886301A
|
|
Modulation of fas and fasl expression
|
|
AU2001268863B2
|
|
Modulation of FAS and FASL expression
|
|
WO0185188A2
|
|
Use of echinacea as a hematinic agent
|
|
AU2336401A
|
|
Hyaluronic acid in the treatment of cancer
|
|
CA2393808A1
|
|
Anti-cancer synthetic oligonucleotides
|
